Emerging Therapeutic Agents for Colorectal Cancer

There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalli, Marianna, Puxeddu, Michela, La Regina, Giuseppe, Gianni, Stefano, Silvestri, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707340/
https://www.ncbi.nlm.nih.gov/pubmed/34946546
http://dx.doi.org/10.3390/molecules26247463
_version_ 1784622412733612032
author Nalli, Marianna
Puxeddu, Michela
La Regina, Giuseppe
Gianni, Stefano
Silvestri, Romano
author_facet Nalli, Marianna
Puxeddu, Michela
La Regina, Giuseppe
Gianni, Stefano
Silvestri, Romano
author_sort Nalli, Marianna
collection PubMed
description There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.
format Online
Article
Text
id pubmed-8707340
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87073402021-12-25 Emerging Therapeutic Agents for Colorectal Cancer Nalli, Marianna Puxeddu, Michela La Regina, Giuseppe Gianni, Stefano Silvestri, Romano Molecules Review There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs. MDPI 2021-12-09 /pmc/articles/PMC8707340/ /pubmed/34946546 http://dx.doi.org/10.3390/molecules26247463 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nalli, Marianna
Puxeddu, Michela
La Regina, Giuseppe
Gianni, Stefano
Silvestri, Romano
Emerging Therapeutic Agents for Colorectal Cancer
title Emerging Therapeutic Agents for Colorectal Cancer
title_full Emerging Therapeutic Agents for Colorectal Cancer
title_fullStr Emerging Therapeutic Agents for Colorectal Cancer
title_full_unstemmed Emerging Therapeutic Agents for Colorectal Cancer
title_short Emerging Therapeutic Agents for Colorectal Cancer
title_sort emerging therapeutic agents for colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707340/
https://www.ncbi.nlm.nih.gov/pubmed/34946546
http://dx.doi.org/10.3390/molecules26247463
work_keys_str_mv AT nallimarianna emergingtherapeuticagentsforcolorectalcancer
AT puxeddumichela emergingtherapeuticagentsforcolorectalcancer
AT lareginagiuseppe emergingtherapeuticagentsforcolorectalcancer
AT giannistefano emergingtherapeuticagentsforcolorectalcancer
AT silvestriromano emergingtherapeuticagentsforcolorectalcancer

Ejemplares similares